About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

OSI webcast tomorrow should have news on the osi-027, as I understand this is the one that belongs to us

A bit of blue makes a change.

it does !! still need something soon me finks !!

Disappointing to say the least but life goes on at ERX.

These four kinases rejoin the panel of apoptosis targets currently subject to collaborative discussions with other parties.'

Contract Update

http://moneyam.uk-wire.com/cgi-bin/articles/200705251455062749X.html

This will be the big one, still accumulating.


19 September 2006

A 50% reduction in breast tumour volume size seen with Eirx lead molecule in
animal studies

'A reduction in tumour volume of 50% is seen by the National Cancer Institute in
America, and other leading authorities as being highly significant' said
Professor Tom Cotter, founder and CSO of EiRx. 'We are now in active
discussions with a developmental company to further develop this molecule and to
prepare it for a future phase 1 clinical trial.

Across the seven major markets, 443,000 women were estimated to have developed
breast cancer in 2004, with an estimated 112,000 dying from the disease. The
incidence is forecast to increase annually at an average rate of 3%. The size
of the market for breast cancer drugs is $6.2 billion; representing 17% of the
total spend of the cancer market.

sp coming back.

Plenty left.

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Left alone :-(

No still here driver ;)

smiler
Well it can't get any worse there must be some good news some where in ERX

Some good posts here chaps I am taking a look at the company, loving the South of Ireland is a big plus too.

All input welcomed unlike some here I like both postive and negative views please.

Have agreat day.

Second day of rises the sp is coming back strong to a more sensible level, after its fall.

might have known--as soon as I move on!!!

mp
Drivers tips theres post for you.

Mercier et Camier - 4 Jun'07 - 18:28 - 20257 of 20271

Taken from another investor site. Thanks to NR1 Trader.

http://investing.reuters.co.uk/news/articleinvesting.aspx?type=smallCapsNews&storyID=2007-06-04T143445Z_01_L04782436_RTRIDST_0_UKSMALLCAPOFTHEWEEK-EIRX.XML

UK small cap of the week - EiRx Therapeutic

LONDON, June 4 (Reuters) - Shares in Ireland's EiRx Therapeutic Plc spiked more than 50 percent last week, making it the top performer among FTSE Small Cap and FTSE AIM All Share companies.

The cancer drug development minnow -- which had previously seen its shares more than halve this year following a steady decline -- suddenly attracted the attention of risk-friendly retail investors, a trader said.

"They (EiRx) had got so low and attracted people who like to gamble .. the shares move around and people love that," he said, adding that the stock held similarities with health firm Ultrasis Plc -- another group which has seen its shares go backwards this year.

Retail share discussion boards have been a hot-bed of discussion among EiRx investors in recent days, with speculation abounding that the firm could be set to receive a grant from the Irish government or even get taken over.

EiRx firm could not immediately be reached for comment.

When posting first-half results at the end of March, EiRx said its aim was to take its cancer therapies to the late preclinical stage of development when other companies typically attract major licensing deals.

"Your board is considering multiple routes ... including grant funding, partnering with larger businesses and in-licensing and M&A options," EiRx said in the statement.

Shares in the company had fallen back slightly by 1430 GMT on Monday, down 5.7 percent at 0.165 penny, valuing it at 4.9 million pounds ($9.7 million). ((Reporting by John Bowker, Editing by Dan Lalor

Reuters Messaging: john.bowker.reuters.com@reuters.net

e-mail: john.bowker@reuters.com;

telephone: +44 20 7542-8454)) ($1 = 0.5033 pound)

Keywords: UKSMALLCAPOFTHEWEEK EIRX/

PH
Cheers for the link.

http://investing.reuters.co.uk/news/articleinvesting.aspx?type=smallCapsNews&storyID=2007-06-04T143445Z_01_L04782436_RTRIDST_0_UKSMALLCAPOFTHEWEEK-EIRX.XML

I believe the results for zyc300 are out this week driver, so keep a close eye out for the rns.. Probably will be Thursday or Friday

Driver.. Reuters posted this this afternoon


EiRx close to announcing Irish govt grant - source
Tue Jun 5, 2007 3:13 PM BST
Email This Article | Print This Article | RSS [-] Text [+]
LONDON, June 5 (Reuters) - Irish drug development company EiRx Therapeutic Plc (ERX.L: Quote, Profile , Research) is close to announcing that it has received a cash grant from the Irish government, a source familiar with the situation said on Tuesday.

The cancer-focused firm has been the subject of retail investor speculation that it could be close to receiving the funds, and featured as Reuters' UK small cap of the week on Monday after a recent 50 percent share price spike.

It is not yet clear how much the grant will be for, or exactly when it will be announced, the source added.

http://investing.reuters.co.uk/news/articleinvesting.aspx?type=allBreakingNews&storyID=2007-06-05T141338Z_01_L05856281_RTRIDST_0_EIRX-GRANT.XML

EiRx could not be reached for comment.



Shares in the loss-making company were up 3 percent at 0.17 pence by 1355 GMT, valuing it at 5 million pounds ($10 million).

It would be nice a little good news considering the recent falls

Thanks ph for keeping us informed

PH
Cheers a nice 50m from the Irish government wouldn't go a miss.